JANX - NASDAQ
Janux Therapeutics, Inc.
$13.59
-1.4%Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
At a Glance
Live Snapshotjanx
Total Liabilities
Last Annual Value
50.70M
3-Year CAGR
5%
5-Year CAGR
10%
10-Year CAGR
19%
Janux Therapeutics, Inc. Competitors Analysis of Total Liabilities
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Janux Therapeutics, Inc. NASDAQ:JANX | 50.70M | 12.0% | 30.3% | N/A | |
 Biohaven Ltd. NYSE:BHVN | 399.38M | 67.3% | 53.2% | N/A | |
 Nuvation Bio Inc. NYSE:NUVB | 289.11M | 160.5% | 57.2% | N/A | |
 Vera Therapeutics, Inc. NASDAQ:VERA | 130.21M | 20.8% | 55.9% | N/A | |
 Maze Therapeutics, Inc. NASDAQ:MAZE | 42.16M | -11.8% | N/A | N/A | |
 Celldex Therapeutics, Inc. NASDAQ:CLDX | 55.82M | 15.3% | 17.3% | -7.2% | |
 Harmony Biosciences Holdings, Inc. NASDAQ:HRMY | 401.41M | 5.2% | 10.2% | N/A | |
 Immunome, Inc. NASDAQ:IMNM | 48.84M | 19.5% | 38.1% | N/A | |
 Sionna Therapeutics, Inc. NASDAQ:SION | 19.12M | -51.4% | N/A | N/A |
Janux Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your JANX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.